Table 1.
Patient characteristics.
| Patient | Sex | Age at ASCT | Duration of MS (years) | Baseline EDSS score | Baseline MRI | Prior treatment | Disease course |
|---|---|---|---|---|---|---|---|
| MS1 | F | 38 | 5 | 7.0 | – | Steroids, interferon-β, natalizumab | SPMS |
| MS2 | F | 22 | 10 | 8.0 | 1 Gd+ | Steroids, interferon-β, natalizumab | SPMS |
| MS3 | F | 53 | 6 | 6.5 | – | Interferon-β, minocycline, steroids, cyclophosphamide | SPMS |
| MS4 | F | 34 | 5 | 8.0 | 2 Gd+ | Interferon-β, steroids, mitoxantrone | PPMS |
| MS5 | F | 37 | 3 | 7.5 | – | Glatiramer acetate, natalizumab, steroids | PPMS |
| MS6 | F | 47 | 13 | 6.5 | Three new T2 lesions | Interferon-β, methotrexate, steroids | SPMS |
| MS7 | F | 57 | 30 | 8.5 | – | Interferon-β, methotrexate, minocycline, steroids | SPMS |
| MS8 | F | 41 | 11 | 8.0 | One new T2 lesion | Interferon-β, mitoxantrone, minocycline, methotrexate | SPMS |
| MS9 | M | 60 | 15 | 6.0 | – | Interferon-β, steroids, mitoxantrone, minocycline, methotrexate | PPMS |
| MS10 | M | 49 | 12 | 6.5 | – | Interferon-β, steroids, methotrexate, mitoxantrone | SPMS |
| MS11 | F | 47 | 16 | 6.5 | – | Steroids, interferon-β, mitoxantrone, minocycline | SPMS |
| MS12 | F | 50 | 17 | 6.5 | – | Interferon-β | SPMS |
| MS13 | F | 48 | 19 | 7.5 | – | Steroids, interferon-β, mitoxantrone, glatiramer acetate | SPMS |
SPMS: secondary progressive multiple sclerosis; PPMS: primary progressive multiple sclerosis; Gd+: gadolinium-enhancing lesion; F: female; M: male; ASCT: autologous stem cell transplantation; MS: multiple sclerosis; EDSS: Expanded Disability Status Scale; MRI: magnetic resonance imaging.